ImmuPharma (LON:IMM) Stock Price Up 28.6% - What's Next?

Key Points

• ImmuPharma plc saw a stock price increase of 28.6% during mid-day trading, with shares trading as high as GBX 12 ($0.16).
• The company reported an earnings per share (EPS) of GBX (0.38) for the last quarter and is projected to post an EPS of -339.0000022 for the current year.
• ImmuPharma specializes in developing peptide-based therapeutics for autoimmune diseases, with its lead program, Lupuzor™, indicating potential for broad therapeutic applications.

ImmuPharma plc (LON:IMM - Get Free Report) rose 28.6% during mid-day trading on Tuesday . The stock traded as high as GBX 12 ($0.16) and last traded at GBX 11.30 ($0.15). Approximately 17,007,168 shares changed hands during mid-day trading, an increase of 97% from the average daily volume of 8,614,648 shares. The stock had previously closed at GBX 8.79 ($0.12).

ImmuPharma Stock Performance

The company has a market capitalization of £56.47 million, a price-to-earnings ratio of -1,269.66 and a beta of 1.53. The firm's 50-day simple moving average is GBX 5.30 and its 200-day simple moving average is GBX 3.58.

ImmuPharma (LON:IMM - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Equities research analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.